A clinical overview of people living with HIV and genitourinary cancer care
Issued Date
2024-01-01
Resource Type
ISSN
17594812
eISSN
17594820
Scopus ID
2-s2.0-85182685889
Journal Title
Nature Reviews Urology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Nature Reviews Urology (2024)
Suggested Citation
Suk-Ouichai C., Coghill A.E., Schabath M.B., Sanchez J.A., Chahoud J., Necchi A., Giuliano A.R., Spiess P.E. A clinical overview of people living with HIV and genitourinary cancer care. Nature Reviews Urology (2024). doi:10.1038/s41585-023-00846-8 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95523
Title
A clinical overview of people living with HIV and genitourinary cancer care
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
The number of people living with HIV infection has been increasing globally. Administration of antiretroviral therapy is effective in controlling the infection for most patients and, as a consequence, people living with HIV (PLWH) now often have a long life expectancy. However, their risk of developing cancer — most notably virus-related cancers — has been increasing. To date, few studies have assessed the risk of genitourinary cancers in PLWH, and robust scientific data on their treatment-related outcomes are lacking. Previous studies have noted that PLWH are at a reduced risk of prostate cancer; however, low adoption and/or availability of prostate cancer screening among these patients might be confounding the validity of this finding. In genitourinary cancers, advanced stage at diagnosis and reduced cancer-specific mortality have been reported in PLWH. These data likely reflect, at least in part, the inequity of health care access for PLWH. Notably, systemic chemotherapy and/or radiotherapy could decrease total CD4+ cell counts, which could, therefore, increase the risk of morbidity and mortality from cancer treatments in PLWH. Immune checkpoint inhibitors have become the therapeutic backbone for many advanced malignancies in the general population; however, most studies validating their efficacy have excluded PLWH owing to concerns of severe adverse effects from immune checkpoint inhibitors themselves and/or related to their immunosuppressed status. To our knowledge, no genitourinary cancer survivorship programme exists that specifically caters to the needs of PLWH. By including PLWH in ongoing cancer trials, we can gain invaluable insights that will help to improve cancer care specifically for PLWH.